ATHX News Alert Athersys (ATHX) 2.12 02/14/2015 12:02:38

New Post Public Reply Private Reply Replies (0) Message Board

Feb 14, 2015 at 1:02 PM

Athersys (ATHX) 2.12 $ATHX

NeoStem: The Levi Strauss Of Cell Therapy
Patrick Young - at Seeking Alpha - Thu Feb 12, 8:05AM CST

VCEL: 3.71 (-0.01), PSTI: 2.91 (+0.01), NBS: 3.78 (+0.14), GSK: 47.94 (+1.99), IMUC: 0.54 (-0.03), KITE: 62.59 (+0.82), BAX: 70.39 (+0.31), ONCE: 46.25 (+0.07), JUNO: 40.52 (+0.18), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)

German Researchers Verify Positive, System-Wide Effect Of Pluristem's PLX Cell Therapy
Sharon di Stefano - Seeking Alpha - Wed Feb 11, 3:31PM CST
Pluristem Therapeutics Inc. (NASDAQ: PSTI ), maker of cell therapy for a wide variety of diseases, recently announced 12-month results from Phase I/II studies with its PLX-PAD off-the-shelf treatment for people who had undergone total hip...
PSTI: 2.91 (+0.01), CYTX: 0.47 (unch), STEM: 1.09 (-0.01), ATHX: 2.12 (unch), CUR: 3.41 (+0.13), CELG: 115.88 (+0.16)

Athersys to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 03, 2:00PM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 17 annual BIO CEO & Investor Conference to be held on February 9-10, 2015 in New York, NY, at The Waldorf Astoria New York.
ATHX: 2.12 (unch)

Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Life Sciences Report - Seeking Alpha - Fri Jan 23, 7:51AM CST
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview...
CPXX: 3.10 (+0.07), RPTP: 9.05 (-0.40), SRPT: 12.76 (+0.11), CLDX: 20.97 (+0.53), PTCT: 53.37 (-0.74), RMTI: 11.17 (+0.15), ATHX: 2.12 (unch), CUR: 3.41 (+0.13)

Athersys and Cell Therapy Catapult Announce Grant to Support Clinical Development of Stem Cell Therapy for Severe Acute Respiratory Condition
GlobeNewswire - Thu Jan 22, 6:00AM CST
Athersys Limited (an affiliate of Athersys, Inc.) (Nasdaq:ATHX) and the Cell Therapy Catapult, a not-for-profit centre, which is focused on the development of the United Kingdom cell therapy industry to increase the nation's health and wealth, are pleased to announce that Athersys Limited has been awarded a grant from Innovate UK, formerly the Technology Strategy Board, which will support a Phase 2a clinical study evaluating the administration of MultiStem cell therapy to acute respiratory distress syndrome (ARDS) patients.
ATHX: 2.12 (unch)

Hot Stock: Athersys, Shares Drop 7.2% (ATHX)
Comtex SmarTrend(R) - Wed Jan 21, 10:06AM CST
Athersys (NASDAQ:ATHX) is one of today's worst performing low-priced stocks, down 7.2% to $1.92 on 1.0x average daily volume. Athersys has traded 584,000 shares thus far today, vs. average volume of 570,000 shares per day. The stock has underperformed the Dow (-7.2% to the Dow's 0.4%) and underperformed the S&P 500 (-7.2% to the S&P's 0.7%) during today's trading.
ATHX: 2.12 (unch)

TiGenix: A Deeply Undervalued Stem Cell Company With Upcoming Catalysts
Logribel Biostocks - Seeking Alpha - Tue Jan 13, 8:59AM CST
TiGenix ( OTC:TGXSF ) -- listed on Euronext Brussels -- is a leading but little known Belgian cell therapy biotech with an advanced adipose-derived allogeneic stem cell product platform in various clinical stages. TiGenix also has a commercialized...
PFE: 34.64 (-0.23), OSIR: 15.95 (+0.28), GSK: 47.94 (+1.99), ATHX: 2.12 (unch)

Athersys to Present at Biotech Showcase 2015
GlobeNewswire - Thu Jan 08, 2:00PM CST
Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the Biotech Showcase(TM) 2015 to be held on January 12-14, 2015 in San Francisco, California, at the Parc 55 Wyndham San Francisco - Union Square.
ATHX: 2.12 (unch)

Nasdaq stocks posting largest volume increases
AP - Tue Jan 06, 5:04PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
ATRI: 332.77 (-2.85), BRID: 7.55 (-0.04), ASBB: 19.90 (+0.05), WVFC: 11.02 (-0.45), CALI: 1.35 (+0.06), SFST: 17.20 (-0.42), WBB: 16.13 (+0.08), ANTH: 3.84 (+0.06), ANAT: 104.90 (-0.10), BTA: 11.32 (-0.07), FBMS: 14.69 (+0.31), ATHX: 2.12 (unch), STXS: 2.27 (+0.13), PZZI: 7.94 (+0.08)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 11:45AM CST

SD: 2.09 (+0.14), FRO: 2.96 (+0.07), EXXI: 4.00 (+0.42), HGG: 6.78 (+0.34), QADA: 20.36 (+0.14), CBMX: 1.83 (-0.16), CHOP: 0.87 (-0.01), CLDN: 16.45 (-0.05), MOC: 2.24 (+0.02), NDRM: 10.76 (+0.22), CALI: 1.35 (+0.06), GDP: 3.58 (+0.29), TNXP: 5.78 (-0.02), ICEL: 5.27 (+0.02), NERV: 4.68 (+0.09), CYTR: 2.96 (+0.23), BBLU: 1.26 (+0.09), ATHX: 2.12 (unch), PEIX: 9.82 (+0.15), PGN: 2.88 (-0.07)

A Look At BrainStorm Cell Therapeutics' ALS Phase IIa Results
Wall Street Titan - at Seeking Alpha - Mon Jan 05, 2:48PM CST

ATHX: 2.12 (unch), BCLI: 3.86 (-0.02)

Stock to Watch: Athersys Up 7.2% (ATHX)
Comtex SmarTrend(R) - Mon Jan 05, 10:36AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 7.2% to $1.78 on 1.7x average daily volume. Thus far today, Athersys has traded 529,000 shares, vs. average volume of 317,000 shares per day. The stock has outperformed the Dow (7.2% to the Dow's -1.5%) and outperformed the S&P 500 (7.2% to the S&P's -1.6%) during today's trading.
ATHX: 2.12 (unch)

Athersys (ATHX) Looks Good: Stock Adds 13.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 8:04AM CST
Athersys, Inc. (ATHX) was a big mover last session, as its shares rose almost 14% on the day.
ATHX: 2.12 (unch), AFFX: 11.45 (+0.02)

Athersys (ATHX) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jan 02, 7:00AM CST
Athersys (ATHX) Shares March Higher, Can It Continue?
ATHX: 2.12 (unch)

Athersys Finishes Enrollment for MultiStem Cell Therapy Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 4:35PM CST
Athersys (ATHX) announced the completion of patient enrolment process for a phase II study on its MultiStem cell therapy.
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20), AMAG: 41.49 (+0.23), ATHX: 2.12 (unch)

Athersys, Inc. (ATHX) in Focus: Stock Jumps 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 8:18AM CST
Athersys, Inc. (ATHX) was a big mover last session, as the company saw its shares rise over 8% on the day.
ACOR: 36.14 (-0.51), ATHX: 2.12 (unch)

Manitowoc and Gilead are big market movers
AP - Mon Dec 29, 3:55PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:
JNJ: 99.62 (+1.18), ECR: 7.29 (+0.12), GILD: 101.90 (+1.10), ATHX: 2.12 (unch), NBG: 1.61 (+0.18), MTW: 21.86 (+0.34), WAG: 76.05 (-0.49)

Athersys Up 5.4%, Shares Break Through Resistance (ATHX)
Comtex SmarTrend(R) - Mon Dec 29, 10:36AM CST
Athersys (NASDAQ:ATHX) is one of today's best performing low-priced stocks, up 5.4% to $1.37 on 1.1x average daily volume. Athersys has traded 289,000 shares thus far today, vs. average volume of 263,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.1%) and outperformed the S&P 500 (5.4% to the S&P's 0.2%) during today's trading.
ATHX: 2.12 (unch)

Athersys completes Phase 2 enrollment
Seeking Alpha - at Seeking Alpha - Mon Dec 29, 6:14AM CST

ATHX: 2.12 (unch)

Athersys Finishes Enrollment of Phase 2 Study of MultiStem(R) Cell Therapy for Ischemic Stroke
GlobeNewswire - Mon Dec 29, 5:30AM CST
Athersys, Inc. (Nasdaq:ATHX) today announced that it has concluded patient enrollment of its Phase 2 clinical study involving administration of Athersys' MultiStem cell therapy to ischemic stroke patients. The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects suffering moderate to moderate-severe ischemic strokes. Athersys expects initial results from the study to be disclosed around the end of the first quarter of 2015.
ATHX: 2.12 (unch)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Simple Home Upgrades That Boost Value Fast

Transform Your Home's Curb Appeal Without Breaking The Bank Every homeowner knows that feeling when you look at your house one day and think, "This could use a little something." Say you're strolling through a neighborhood in Fulton, N.Y., and notice a gem. It's not a brand new build, but it gleams with character. You bet it's had a few smart touches that could apply...

Jaguar Promise Tackles College Cost for Texas Students

Transforming Aspirations into Achievements In the heart of San Antonio, something’s cooking at A&M University-San Antonio, and it's not just the classic breakfast tacos. They've hit a record-breaking enrollment of 7,697 students this Fall, with 1,322 being fresh-faced first-timers. And while that might grab your attention, the real headliner is their Jaguar Promise...

Trial for Former OB/GYN Arthur Park Begins in Bakersfield

A Somber Day for Justice in Bakersfield There’s a buzz in the air, thick with anticipation and grief, as a trial seven years in the making kicks off in Bakersfield. It’s a significant affair, marking a turning point in a saga that’s shadowed the region with untold grief and unresolved accountability. We’re talking about the trial of Arthur Park, a former OB/GYN,...

Navigating Battery Compliance for AI Data Centers

Untangling the Web of Global Battery Compliance Amid clamor about AI's insatiable appetite for energy storage, the rules around shipping, installing, and handling data center batteries have become a tangled web. From Waxahachie, Texas, Americase International plans to take the stage at the OCP Global Summit on October 15, 2026, to spearhead a discussion on bridging the...

Partner Valuation Advisors Bolsters Team with Eichman

Eichman Joins Partner Valuation Advisors as MD Turns out the buzz in real estate appraisal isn’t just about property values these days; it's about who's valuing them. Just ask Partner Valuation Advisors, who are realigning their chess pieces by bringing seasoned pro Justin Eichman, MAI, on board as Managing Director. Talk about playing your cards right. A Heavyweight in...

Omega Point's MCP Secures Anthropic Verification

In a world where investment decisions ride on razor-thin margins, Omega Point's MCP gains top-tier verification. Anthropic's seal of approval is stamped firmly on it, signalling to the wise investors out there that this engine ain't smoking mirrors. Since May, this player has been doing the rounds, but now, with Anthropic’s verification, it’s like Omega Point just...

Tessa AI: Revolutionizing Biomedical Research with AI

Shaking Up Research Evaluation When Siensmetrica decided it was high time for a name change, morphing into Tessa AI wasn't just a cosmetic shift. It was a nod to what stakeholders were already calling it and laid the ground for a broader mission statement. They're not sitting on their hands; they're crafting tools that tackle the scientific life cycle from start to...

Montesodi 2023: A Fresh Chapter in Chianti Excellence

A Glass Filled with History and Nature's Whimsy When you pour a glass of Montesodi 2023, you’re not just tasting wine but a story—a saga that blends Tuscany’s rich vineyard history with last year's unpredictable weather. Marchesi Frescobaldi, a name that’s seen it all over its thousand years, has once again shown us how resilience and tradition can marry with...

Truck Drivers USA & Career Driver Unveil New Driver Agent

Revolutionizing Driver-Carrier Connections In today's cranking transportation scene, Truck Drivers USA (TDUSA) and Career Driver have taken a bold step to change up the driver recruitment game. They've launched what's being labeled as the first 'driver agent' within the Career Driver mobile app. It's the talk of the town in Sherwood, Arkansas, these days. This isn't just...